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tionnaires and physical tests, which are not practical in daily clinical routine. At
our department all patients are assessed daily by the nursing staff for their nurs-
ing demands, including activities of daily living (ADL; eat/drink, stool, mobility,
hygiene) in 3 different gradings (not, partly, fully self-sufﬁcient).
Purpose: We hypothesised that theses data is enough to calculate a predictive
frailty score.
Methods: We performed a retrospective analysis (inclusion of: Type-1 AMI, ≥65
years, years 2012–2014; exclusion: cardiogenic shock) and collected the patient’s
anamnesis and ADL assessments before discharge. Depending on the grading
within each ADL category (0 points = not, 1 point = partly, 2 points = fully self-
sufﬁcient, respectively), patients were stratiﬁed into 3 different groups: severe (0–
3 points), moderate (4–6 points) and not frail (7–8 points), respectively. Primary
endpoint was all-cause mortality on 31st December 2015. We performed a de-
scriptive analysis of data. Differences in mortality were assessed by log-rank test,
independent predictors were investigated by linear and cox-regression models.
Results: We identiﬁed 396 patients (35.6% STEMI, 44.4% females, mean age
76.7 years). Of those, 5.6% were severe, 22.5% were moderate, and 72.0% were
non frail according to our score. Overall all-cause mortality was 25.3% (median
follow-up 2.5 years). Frail patients were older (p=0.001), had signiﬁcantly more of-
ten STEMI at presentation (p=0.022), increased conservative therapy (p<0.001),
known heart failure (p=0.025), atrial ﬁbrillation (p<0.001), a history of stroke
(p=0.043) and were more likely to be female (p=0.012). Independent predic-
tors for frailty score at discharge (adjusted for baseline characteristics) were age
(OR-0.38; -0.064–0.012; p=0.004), reperfusion therapy (OR 0.989; 0.548–1.43;
p<0.001) and atrial ﬁbrillation (OR-1.242; -1,769- -0.716; p<0.001).
Mortality rates for frailty cohorts are depicted in Fig. 1 (log-rank <0,0001 be-
tween groups). Independent predictors for long-term all-cause mortality were
frailty score (p<0.0001; HR 0.755; 0.687–0.830), age (p=0,001; HR 1.05; 1.021–
1.080), kidney function (MDRD) (p=0.002; HR 0.986; 0.978–0.995), known heart
failure (p=0.017; HR1.911; 1.121–3.257) and reperfusion therapy (p=0.032; HR
0.586; 0.36–0.955). There was no interaction between age and the frailty score
(p=0.636).
All-cause mortality of frailty groups
Conclusion:Our frailty score is very easy to assess and to calculate. After adjust-
ment for prognostic baseline characteristics, our score serves as an independent
predictor for long-term all-cause mortality in patients after AMI ≥65 years.
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Validity of accelerometer cut-points and level of free-living physical
activity in the oldest old patients with coronary artery disease
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Sahlgrenska Academy, Gothenburg; 2Karolinska Institute, Dept. of Neurobiology,
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Background: To improve our understanding of physical activity in the oldest old
patients with coronary artery disease (CAD), accurate assessments such as ac-
celerometry are important. There is no consensus on applicable accelerometer
cut-points for deﬁning intensity levels for the oldest old patients with CAD.
Purpose: The purpose of this study was (1) to assess the validity of three existing
intensity cut-points for accelerometers for the oldest old patients with CAD and
(2) to assess free-living physical activity, applying the cut-points with the highest
validity for assessing moderate intensity, among these patients.
Methods: A total of 24 patients with CAD, mean age 87.5±3.7 years, participated
in the study at a university hospital in Sweden. To assess the validity of the exist-
ing cut-points, the patients walked at different speeds wearing the accelerometer
at a pace corresponding to individualised perceived exertion at light, moderate,
and high intensity according to the Borg-RPE scale. For the free-living physical
activity assessment, the patients wore the accelerometer for seven consecutive
days. The percentage agreement for light, moderate and high intensity cut-points,
as well as ROC curves, was used to identify the sensitivity and speciﬁcity of the
existing cut-points for moderate intensity.
Results: The cut-point for moderate intensity at 1,041 counts per minute accord-
ing to Copeland showed the highest validity. The sensitivity was 0.739 and the
speciﬁcity was 0.609. In a free-living setting, the patients spent 11 of 13.5 (81%)
waking hours in a sedentary position and, of the 2.5 hours of being active, 19 min-
utes (2%) were at least at moderate intensity. Nine of 24 patients (38%) reached
20 minutes of moderate- to vigorous-intensity physical activity three days a week,
according to guidelines for exercise-based cardiac rehabilitation.
Conclusions: The existing cut-points for physical activity intensity according to
Copeland were found to be valid for the oldest old patients with CAD. Accelerom-
etry is a feasible method which can help to further improve our understanding of
free-living physical activity behaviour and to assess relationships between free-
living physical activity and health outcomes among the oldest old patients with
CAD.
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A serum biomarker reﬂecting collagen type I degradation (C1M) is an
independent risk factor for acute myocardial infarction in
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D.M. Bertelsen1, S. Holm Nielsen2, J.S. Neergaard3, M. Karsdal3, H.B. Nielsen4.
1University of Copenhagen, Department of Anaesthesiology, Copenhagen,
Denmark; 2Technical University of Denmark, Department of Biotechnology and
Biomedicine, Kgs. Lyngby, Denmark; 3Nordic Bioscience, Herlev, Denmark;
4ProScion, Herlev, Denmark
Background/Introduction: Cardiovascular disease (CVD) is the leading cause
of death in postmenopausal women, and symptoms of ischemic heart disease
(IHD) and acute myocardial infarction (AMI) are often overlooked. With the loss
of estrogen production collagen stability is affected with potential of an increased
risk of unstable plaques in coronary vessels. Collagen type I, a major component
of the cardiac extracellular matrix (ECM), is cleaved by matrix metalloproteinases
(MMPs) and known to be active remodeled in CVD.
Purpose: In a large prospective cohort, we explored whether increased MMP-
mediated degradation of collagen type I (C1M) measured in serum can be used
as a prognostic biomarker for AMI.
Methods: From 1999–2001, 5,855 postmenopausal women aged 49–89 partic-
ipated in the prospective epidemiologic risk factor (PERF) study. Demographics
and serum samples were collected at time of enrollment. AMI, re-infarction, or
death subsequent to AMI were collected from the Danish National Registry ul-
timo 2014. Serum C1M levels were measured by ELISA and evaluated towards
the association between C1M and AMI. Associations between C1M and AMI were
assessed by a Kaplan-Meier Survival Curve to demonstrate incidents of AMI over
time in relation to C1M levels divided into quartiles. A Multivariate cox proportional
hazard analysis was used to assess the association between C1M levels and AMI
incidents. Women diagnosed with AMI prior to PERF enrollment were excluded
from the analysis.
Results: A total of 316 women were diagnosed with AMI following PERF enroll-
ment. C1M was signiﬁcantly associated with AMI; patients in the highest C1M
quartile were 1.6 times more likely to decrease in AMI-free survival than patients
in the lowest quartile (p=0.0055). By multivariate Cox proportional-hazard analy-
sis on log2 transformed C1M, the risk of AMI increased by 18% (p=0.03). When
doubling the C1M level, and with C1M levels above the pre-speciﬁed cut-off (>56
ng/mL), the risk for AMI increased by 33% (p=0.025).
Conclusion: In postmenopausal women serum C1M is associated with AMI and
high levels are an independent risk factor for AMI.
Acknowledgement/Funding: The Danish Research Foundation
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Background: Optimal target level of low-density lipoprotein cholesterol (LDL-C)
for prevention of cardiovascular disease is not estimated.
Purpose: The purpose of this study was to investigate (1) relationship between
LDL-C and vascular function in patients with and without statin therapy, and (2)
optimal level of LDL-C for maintenance of normal vascular function.
Methods: We evaluated ﬂow-mediated vasodilation (FMD), nitroglycerine-
induced vasodilation, and serum level of LDL-C in 1349 subjects with and without
statin therapy. First, serum level of LDL-C was categorized as high (>100mg/dL)
and non-high (≤100 mg/dL). Then non-high level of LDL-C was additionally cate-
gorized as low (≤70 mg/dL) and moderate (70.1–100 mg/dL).
Results: FMD and nitroglycerine-induced vasodilation were negatively correlated
with LDL-C in 957 subjects without statin therapy, but not in 392 subjects with
statin therapy. In statin naïve subjects, non-high LDL-C was associated with the
decrease in the odds ratio of low tertile of FMD (OR: 0.62, 95% CI: 0.45–0.85;
P=0.003) and nitroglycerine-induced vasodilation (OR: 0.69, 95% CI: 0.50–0.96;
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